Abstract: OBJECTIVES: Patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (aNSCLC) are at high risk of developing brain metastases (BM), thus entailing significant clinical and economic burden. The aim of this study was to...
Abstract: OBJECTIVES: To evaluate the cost-effectiveness of upadacitinib in patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response, lost response or were intolerant to either conventional therapy (bio-naive) or a...
Abstract: OBJECTIVES: Juvenile idiopathic arthritis is the most common chronic rheumatic disease in childhood. In this light, the aim of the present study was to perform a cost-comparison analysis of tofacitinib compared to currently marketed available treatment for...
Abstract: OBJECTIVES: To evaluate the cost-effectiveness of pemigatinib compared to oxaliplatin-L-folinic-acid and fluorouracil plus active symptom control (mFOLFOX+ASC) and ASC alone for the treatment of patients with advanced or metastatic cholangiocarcinoma (CCA)...
Abstract: OBJECTIVES: To evaluate the cost-effectiveness of upadacitinib in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), who have responded inadequately to conventional treatment (NSAIDs), in Greece. METHODS: A cost-effectiveness model,...